Search Results

You are looking at 31 - 40 of 471 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Margaret A. Tempero

Panel Adds to Pancreatic Cancer Recommendations For the first time in decades, advances in diagnostics and adjuvant therapies appear to be improving outcomes in pancreatic cancer. These advances are reflected in additions to the NCCN Clinical

Full access

Jacob Klapper and Thomas A. D’Amico

. The thoracoscopic approach is oncologically equivalent to thoracotomy, while resulting in fewer complications, improved quality of life, shorter length of stay, and superior compliance with adjuvant therapies. 6 – 8 Oncologic Outcomes The

Full access

Presenter: Stephen W. Behrman

, patients are categorized based on the predominant subtype. Although the prognostic value of subtyping relative to adjuvant therapy and neoadjuvant therapy remains unclear, Dr. Behrman underscored the importance of subtyping for future therapeutic

Full access

Paul B. Chapman

analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system . J Clin Oncol 2001 ; 19 : 3622 – 3634 . 2 Kirkwood JM Strawderman MH Ernstoff MS . Interferon alfa-2b adjuvant therapy of high

Full access

Ya-Fu Cheng, Wei-Heng Hung, Heng-Chung Chen, Ching-Yuan Cheng, Ching-Hsiung Lin, Sheng-Hao Lin, and Bing-Yen Wang

offer surgical treatment and more likely to use induction therapy before resection, whereas European surgeons preferred to offer OP followed by adjuvant therapy in select cases of N2 disease. Different therapeutic methods were compared in previous

Full access

Jeffrey S. Dome, Elizabeth A. Mullen, David B. Dix, Eric J. Gratias, Peter F. Ehrlich, Najat C. Daw, James I. Geller, Murali Chintagumpala, Geetika Khanna, John A. Kalapurakal, Lindsay A. Renfro, Elizabeth J. Perlman, Paul E. Grundy, and Conrad V. Fernandez

patients with very low risk WT, as described in the text, who were candidates to receive no adjuvant therapy. The structure of the AREN ‘0’ studies is depicted in Figure 2 . An expanded menu of biologic and clinical prognostic factors, including

Full access

Eric Jonasch

Center, and Vice Chair of the NCCN Guidelines Panel for Kidney Cancer, as he introduced his presentation at the NCCN 23rd Annual Conference. Adjuvant Therapy Five adjuvant therapy trials have been conducted in renal cell carcinoma (RCC). The ASSURE

Full access

Louis Burt Nabors

different: for RTOG 9402, neoadjuvant therapy consisted of PCV chemotherapy before RT, and in EORTC 26951 adjuvant therapy consisted of PCV chemotherapy after RT. However, toxicity from the PCV regimen was an issue in both studies. “A lot of patients did not

Full access

Presenter: Eileen M. O’Reilly

pembrolizumab to maintenance olaparib, with arms stratified by mutation profile and exceptional response to platinum therapy. Adjuvant Therapy: Overall Survival Advantage Proven Based on the phase III PRODIGE 24/CCTG PA.6 trial, the state-of-the-art adjuvant

Full access

Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer

threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000;18:1709–1717. Breast Cancer Mortality Figure 3 shows age-specific breast cancer incidence rates in the United States from the SEER database for 1975 to 2003 for women aged 40